United States Drug Enforcement Administration

WASHINGTON – The U.S. Drug Enforcement Administration has seen an increase in burglaries at independent pharmacies across the country. Nearly 900 burglaries involving the theft of controlled substances were reported to DEA in 2023. Stolen prescription medications adversely impact these small businesses while also putting patients and the community at...

WASHINGTON – Today, DEA Administrator Anne Milgram announced the release of the 2024 National Drug Threat Assessment (NDTA), DEA’s comprehensive strategic assessment of illicit drug threats and trafficking trends endangering the United States. For more than a decade, DEA’s NDTA has been a trusted resource for law enforcement agencies, policy...

WASHINGTON, D.C. – The U.S. Drug Enforcement Administration announced today a settlement with pharmaceutical distributor Morris & Dickson Co., LLC for failing to maintain effective controls against diversion of controlled substances, including failure to report to DEA thousands of unusually large orders of oxycodone and hydrocodone. Morris & Dickson, which...

WASHINGTON – Today, the U.S. Drug Enforcement Administration announced administrative actions against six DEA-registered companies which, together, failed to account for more than a million doses of opioids. Under DEA initiative “Operation Bottleneck,” DEA served an Immediate Suspension Order and five Orders to Show Cause over a one-month period from...

WASHINGTON – Today, ahead of the expiration of the COVID-19 Public Health Emergency (PHE), the Drug Enforcement Administration (DEA) and the Substance Abuse and Mental Health Services Administration (SAMHSA) issued the “Temporary Extension of COVID-19 Telemedicine Flexibilities for Prescription of Controlled Medications” – a temporary rule that extends telemedicine flexibilities...

WASHINGTON - Today, the Drug Enforcement Administration announced proposed permanent rules for the prescribing of controlled medications via telemedicine, expanding patient access to critical therapies beyond the scheduled end of the COVID-19 public health emergency. The public will be able to comment for 30 days on the proposed rules. The...

WASHINGTON -- Today, DEA served an Order to Show Cause on Truepill, a retail pharmacy that is alleged to have wrongfully filled thousands of prescriptions for stimulants used in the treatment of Attention Deficit/Hyperactivity Disorder (ADHD). Truepill was the pharmacy for telehealth companies, including Cerebral, that marketed ADHD treatments, including...

WASHINGTON – Yesterday, DEA and the Office of the Special Narcotics Prosecutor for the City of New York announced a significant seizure of fentanyl. Two individuals in New York have been charged following the seizure of approximately 300,000 rainbow fentanyl pills, 20 pounds of fentanyl in white and blue powder...

WASHINGTON – The U.S. Drug Enforcement Administration today announced the results of an enforcement operation that spanned from May to September and resulted in significant fentanyl seizures across the United States. As part of the One Pill Can Kill initiative, the DEA and its law enforcement partners seized more than...

WASHINGTON – The Drug Enforcement Administration is advising the public of an alarming emerging trend of colorful fentanyl available across the United States. Since August 2022, DEA and our law enforcement partners seized brightly-colored fentanyl and fentanyl pills in 26 states. Dubbed “rainbow fentanyl” in the media, this trend appears...